Last reviewed · How we verify
TIV followed by LAIV
TIV (inactivated influenza vaccine) primes the immune system, followed by LAIV (live attenuated influenza vaccine) to boost mucosal and systemic immunity against influenza.
TIV (inactivated influenza vaccine) primes the immune system, followed by LAIV (live attenuated influenza vaccine) to boost mucosal and systemic immunity against influenza. Used for Influenza prevention in adults and children.
At a glance
| Generic name | TIV followed by LAIV |
|---|---|
| Also known as | Seasonal Influenza Vaccines |
| Sponsor | University of Rochester |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This sequential vaccination strategy uses an inactivated vaccine first to establish systemic immunity, then administers a live attenuated vaccine to enhance mucosal immunity and broaden the immune response. The combination approach aims to provide superior protection against multiple influenza strains compared to either vaccine alone.
Approved indications
- Influenza prevention in adults and children
Common side effects
- Injection site soreness or swelling
- Nasal congestion or runny nose
- Fever or chills
- Myalgia
Key clinical trials
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
- Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection (PHASE1)
- Woodsmoke Exposure, Influenza Infection, and Nasal Immunity (PHASE4)
- Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children (PHASE4)
- Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine (PHASE1)
- The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (PHASE1)
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (PHASE1)
- Efficacy & Safety of Nasal Influenza Immunisation in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIV followed by LAIV CI brief — competitive landscape report
- TIV followed by LAIV updates RSS · CI watch RSS
- University of Rochester portfolio CI